1004OFinal overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study. (23rd October 2018) - Cavalli, F; Jin, J; Pylypenko, H; Verhoef, G; Siritanaratkul, N; Drach, J; Raderer, M; Mayer, J; Pereira, J; Tumyan, G; Okamoto, R; Nakahara, S; et al.